Joel Solis
Impact in
- Epidemiology top 2%
- Liver Disease Diagnosis and Treatment
- Infectious Diseases top 10%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
Papers in
-
- SARS-CoV-2 and COVID-19 Research 4
- COVID-19 Clinical Research Studies 2
-
- Liver Disease Diagnosis and Treatment 1
- Journals
- JAMA Network Open (3 papers)The Lancet (1 paper)EBioMedicine (1 paper)The Lancet Infectious Diseases (1 paper)JAMA (1 paper)
- Partner nations
- United KingdomGermanyBelgium
In The Last Decade
Joel Solis
8 papers receiving 1.4k citations
Joel Solis's Hit Papers
Peers
Comparison fields: 5 of 46
- Epidemiology 681
- Infectious Diseases 207
- Hepatology 84
- Oncology 45
- Toxicology 6
Countries citing papers authored by Joel Solis
This map shows the geographic impact of Joel Solis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Solis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Solis more than expected).
Fields of papers citing papers by Joel Solis
This network shows the impact of papers produced by Joel Solis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Solis. The network helps show where Joel Solis may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Hit paper breakdown → | 2019 | 1078 |
| 2 | Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 Hit paper breakdown → | 2022 | 211 |
| 3 | 2022 | 64 | |
| 4 | 2023 | 14 | |
| 5 | 2021 | 11 | |
| 6 | 2023 | 8 | |
| 7 | 2024 | 3 | |
| 8 | 2025 | 2 |
About Joel Solis
Joel Solis is a scholar working on Infectious Diseases, Epidemiology, Nuclear Energy and Engineering, Waste Management and Disposal and Organic Chemistry, having authored 8 papers that have together received 1.4k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (4 papers), COVID-19 Clinical Research Studies (2 papers) and Liver Disease Diagnosis and Treatment (1 paper). The work is most often cited by research in Epidemiology (681 citations), Infectious Diseases (207 citations), Hepatology (84 citations), Oncology (45 citations) and Toxicology (6 citations). Joel Solis has collaborated with scholars based in United Kingdom, Germany and Belgium. Their work appears in journals such as JAMA Network Open, The Lancet, EBioMedicine, The Lancet Infectious Diseases and JAMA.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.